State Street’s Scinai Immunotherapeutics SCNI Stock Holding History

State Street’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-85	Closed	-$200K	–	4924
2021 Q4	$200K	Buy	85 +6	+8%	+$12.4K	﹤0.01%	4353
2021 Q3	$175K	Sell	79 -1	-1%	-$2.57K	﹤0.01%	4403
2021 Q2	$230K	Buy	80 +2	+3%	+$6.22K	﹤0.01%	4162
2021 Q1	$296K	Buy	78 +7	+10%	+$30.6K	﹤0.01%	3793
2020 Q4	$200K	Buy	71 +55	+344%	+$666K	﹤0.01%	3756
2020 Q3	$645K	Buy	+16	New	+$614K	﹤0.01%	3532

Other funds holding SCNI

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TPWA

TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

State Street's SCNI Position: Q1 2022 in Review

State Street sold out of Scinai Immunotherapeutics (SCNI) in Q1 2022, closing a stake of 85 shares — an estimated $200K sold.

State Street first reported a position in SCNI in Q3 2020 and held it in 6 quarters. The position peaked at $645K in Q3 2020. 17 funds tracked by Wall St. Rank hold SCNI as of Q1 2022.

State Street reported no remaining Scinai Immunotherapeutics position as of Q1 2022 after selling out during the quarter.
State Street sold 85 Scinai Immunotherapeutics shares in Q1 2022, an estimated $200K.
State Street first reported a position in Scinai Immunotherapeutics in Q3 2020 and held it in 6 quarters.
State Street's Scinai Immunotherapeutics position peaked at $645K in Q3 2020.
17 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2022.

Based on State Street's 13F filing for Q1 2022, filed 16 May 2022.